86 / 140
208
40. Esmerian M, Mitri Z, Habbal M-Z, Geryess E, Zaatari G, Alam S, et al.
Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and
acenocoumarol in a sample of Lebanese people. J Clin Pharmacol.
2011;51:1418–28.
41. Thijssen H, Drittij M, Vervoort L, de Vries-Hanje J. Altered
pharmacokinetics of R- and S-acenocoumarol in a subject
heterozygous for CYP2C9*3. Clin Pharmacol Ther. 2001;70:292–
8.
42. Schalekamp T, van Geest-Daalderop J, de Vries-Goldschmeding H,
Conemans J, Bernsen M, de Boer A. Acenocoumarol stabilization is
delayed in CYP2C93 carriers. Clin Pharmacol Ther. 2004;75:394–
402.
43. Visser L, van Vliet M, van Schaik R, Kasbergen A, De Smet P, Vulto A,
et al. The risk of overanticoagulation in patients with cytochrome
P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or
phenprocoumon. Pharmacogenetics. 2004;14:27–33.
44. Tàssies D, Freire C, Pijoan J, Maragall S, Monteagudo J, Ordinas
A, et al. Pharmacogenetics of acenocoumarol: cytochrome P450
CYP2C9 polymorphisms influence dose requirements and stability
of anticoagulation. Haematologica. 2002;87:1185–91.
45. Verstuyft C, Morin S, Robert A, Loriot M, Beaune P, Jaillon P, et al.
Early acenocoumarol overanticoagulation among cytochrome
P450 2C9 poor metabolizers. Pharmacogenetics. 2001;11:735–
7.
46. Miranda C, Roco Á, Garay J, Squicciarini V, Tamayo E, Agúndez J,
et al. Determinación del polimorfismo de CYP2C9*2 y su relación
con la farmacocinética de acenocumarol en voluntarios sanos. Rev
Chil Cardiol. 2011;30:218–24.
47. Gage B, Eby C, Milligan P, Banet G, Duncan J, McLeod H. Use of
pharmacogenetics and clinical factors to predict the maintenance
dose of warfarin. Thromb Haemost. 2004;91:87–94.
48. Kamali F, Khan T, King B, Frearson R, Kesteven P, Wood P, et
al. Contribution of age, body size, and CYP2C9 genotype to
anticoagulant response to warfarin. Clin Pharmacol Ther.
2004;75:204–12.
49. Hillman M, Wilke R, Caldwell M, Berg R, Glurich I, Burmester J.
Relative impact of covariates in prescribing warfarin according to
CYP2C9 genotype. Pharmacogenetics. 2004;14:539–47.
50. Sconce E, Khan T, Wynne H, Avery P, Monkhouse L, King B, et al. The
impact of CYP2C9 and VKORC1 genetic polymorphism and patient
characteristics upon warfarin dose requirements: proposal for a
new dosing regimen. Blood. 2005;106:2329–33.
51. Gage B, Eby C, Johnson J, Deych E, Rieder M, Ridker P, et al. Use of
pharmacogenetic and clinical factors to predict the therapeutic
dose of warfarin. Clin Pharmacol Ther. 2008;84:326–31.
52. Wadelius M, Chen L, Lindh J, Eriksson N, Ghori M, Bumpstead S,
et al. The largest prospective warfarin-treated cohort supports
genetic forecasting. Blood. 2009;113:784–92.
53. Perera M, Cavallari L, Limdi N, Gamazon E, Konkashbaev A,
Daneshjou R, et al. Genetic variants associated with warfarin
dose in African-American individuals: a genome-wide association
study. Lancet. 2013;382:790–6.
54. Verhoef T, Redekop W, Daly A, Van Schie R, De Boer A, Maitland-Van
Der Zee AH. Pharmacogenetic-guided dosing of coumarin
anticoagulants: Algorithms for warfarin, acenocoumarol and
phenprocoumon. Br J Clin Pharmacol. 2014;77:626–41.
55. Van Schie R, Wessels J, le Cessie S, de Boer A, Schalekamp T, van
der Meer F, et al. Loading and maintenance dose algorithms for
phenprocoumon and acenocoumarol using patient characteristics
and pharmacogenetic data. Eur Heart J. 2011;32:1909–17.
56. Scott S, Sangkuhl K, Stein C, Hulot J-S, Mega J, Roden D, et
al. Clinical Pharmacogenetics Implementation Consortium
guidelines for CYP2C19 genotype and clopidogrel therapy: 2013
update. Clin Pharmacol Ther. 2013;94:317–23.
57. Zhu H-J, Wang X, Gawronski B, Brinda B, Angiolillo D, Markowitz
J. Carboxylesterase 1 as a determinant of clopidogrel metabolism
and activation. J Pharmacol Exp Ther. 2013;344:665–72.
58. Trenk D, Hochholzer W. Genetics of platelet inhibitor treatment. Br
J Clin Pharmacol. 2014;77:642–53.
59. Holmes M, Perel P, Shah T, Hingorani A, Casas J. CYP2C19
genotype, clopidogrel metabolism, platelet function, and
cardiovascular events: a systematic review and meta-analysis.
JAMA. 2011;306:2704–14.
60. Mega J, Simon T, Collet J-P, Anderson J, Antman E, Bliden K, et al.
Reduced-function CYP2C19 genotype and risk of adverse clinical
outcomes among patients treated with clopidogrel predominantly
for PCI: a meta-analysis. JAMA. 2010;304:1821–30.
61. Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser
T, et al. Impact of P-glycoprotein on clopidogrel absorption. Clin
Pharmacol Ther. 2006;80:486–501.
62. Su J, Xu J, Li X, Zhang H, Hu J, Fang R, et al. ABCB1 C3435T
polymorphism and response to clopidogrel treatment in coronary
artery disease (CAD) patients: a meta-analysis. PLoS One.
2012;7:e46366.
63. Verschuren J, Trompet S, Wessels J, Guchelaar H-J, de Maat M,
Simoons M, et al. A systematic review on pharmacogenetics in
cardiovascular disease: is it ready for clinical application? Eur
Heart J. 2012;33:165–75.
64. Wilke R, Ramsey L, Johnson S, Maxwell W, McLeod H, Voora D, et
al. The clinical pharmacogenomics implementation consortium:
CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.
Clin Pharmacol Ther. 2012;92:112–7.
65. Ramsey L, Johnson S, Caudle K, Haidar C, Voora D, Wilke R, et al. The
clinical pharmacogenetics implementation consortium guideline
for SLCO1B1 and simvastatin-induced myopathy: 2014 update.
Clin Pharmacol Ther. 2014;96:423–8.
66. Carr D, O’Meara H, Jorgensen A, Campbell J, Hobbs M, McCann G,
et al. SLCO1B1 genetic variant associated with statin-induced
myopathy: a proof-of-concept study using the clinical practice
research datalink. Clin Pharmacol Ther. 2013;94:695–701.
67. Danik J, Chasman D, MacFadyen J, Nyberg F, Barratt B, Ridker
P. Lack of association between SLCO1B1 polymorphisms and
clinical myalgia following rosuvastatin therapy. Am Heart J.
2013;165:1008–14.
68. De Keyser C, Peters B, Becker M, Visser L, Uitterlinden A, Klungel
O, et al. The SLCO1B1 c.521T>C polymorphism is associated with
dose decrease or switching during statin therapy in the Rotterdam
Study. Pharmacogenet Genomics. 2014;24:43–51.
[REV. MED. CLIN. CONDES - 2015; 26(2) 198-209]